Reversal of age-associated memory impairment by rosuvastatin in rats

Experimental Gerontology

Volumn 45, Issue 5, 2010, Pages 351-356

  Rech, Rafael Luiz ^a   de Lima, Maria Noêmia Martins ^a,b   Dornelles, Arethuza ^a   Garcia, Vanessa Athaíde ^a   Alcalde, Luisa Azambuja ^a   Vedana, Gustavo ^a   Schröder, Nadja ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Aging; Iron; Neurodegeneration; Rats; Recognition memory; Rosuvastatin; Statins

Indexed keywords

IRON; ROSUVASTATIN;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; LONG TERM MEMORY; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; RECOGNITION; SHORT TERM MEMORY; SINGLE DRUG DOSE;

AGING; ANIMALS; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRON; MEMORY DISORDERS; MOTOR ACTIVITY; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES;

ANIMALIA; RATTUS;

EID: 77951093940     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2010.02.001     Document Type: Article

References (66)

1. Ajith T.A., Riji T., Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin. Exp. Pharmacol. Physiol. 2008, 35(5-6):625-629.
2. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341(26):1989-1995.
3. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., Bennett D.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008, 70(19 Pt 2):1795-1802.
4. Benkovic S.A., Connor J.R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 1993, 338:97-113.
5. Berg D., Youdim M.B. Role of iron in neurodegenerative disorders. Top. Magn. Reson. Imaging 2006, 17(1):5-17.
6. Bernick C., Katz R., Smith N.L., Rapp S., Bhadelia R., Carlson M., Kuller L. Statins and cognitive function in the elderly: the cardiovascular health study. Neurology 2005, 65(9):1388-1394. Cardiovascular Health Study Collaborative Research Group.
7. Bösel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P.C., Megow D., Dirnagl U., Hörtnagl H., Fink K.B., Endres M. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 2005, 92(6):1386-1398.
8. Cramer C., Haan M.N., Galea S., Langa K.M., Kalbfleisch J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71(5):344-350.
9. Dal-Pizzol F., Klamt F., Frota M.L.C., Andrades M.E., Caregnato F.F., Vianna M.R.M., Schröder N., Quevedo J., Izquierdo I., Archer T., Moreira J.C.F. Neonatal iron exposure induces oxidative stress in adult Wistar rats. Dev. Brain Res. 2001, 130:109-114.
10. de Lima M.N., Dias C.P., Torres J.P., Dornelles A., Garcia V.A., Scalco F.S., Guimarães M.R., Petry R.C., Bromberg E., Constantino L., Budni P., Dal-Pizzol F., Schröder N. Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol. Aging 2008, 29(7):1052-1059.
11. de Lima M.N., Presti-Torres J., Garcia V.A., Guimarães M.R., Scalco F.S., Roesler R., Schröder N. Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology 2008, 55(5):788-792.
12. de Lima M.N., Presti-Torres J., Caldana F., Grazziotin M.M., Scalco F.S., Guimarães M.R., Bromberg E., Franke S.I., Henriques J.A., Schröder N. Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats. Eur. J. Pharmacol. 2007, 570(1-3):111-114.
13. de Lima M.N., Luft T., Roesler R., Schröder N. Temporary inactivation reveals an essential role of the dorsal hippocampus in consolidation of object recognition memory. Neurosci. Lett. 2006, 405:142-146.
14. de Lima M.N., Polydoro M., Laranja D.C., Bonatto F., Bromberg E., Moreira J.C., Dal-Pizzol F., Schroder N. Recognition memory impairment and brain oxidative stress induced by postnatal iron administration. Eur. J. Neurosci. 2005, 21(9):2521-2528.
15. de Lima M.N., Laranja D.C., Caldana F., Grazziotin M.M., Garcia V.A., Dal-Pizzol F., Bromberg E., Schroder N. Selegiline protects against recognition memory impairment induced by neonatal iron treatment. Exp. Neurol. 2005, 196(1):177-183.
16. de Lima M.N., Laranja D.C., Caldana F., Bromberg E., Roesler R., Schroder N. Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp. Gerontol. 2005, 40(6):506-511.
17. Ding B., Chen K.M., Ling H.W., Sun F., Li X., Wan T., Chai W.M., Zhang H., Zhan Y., Guan Y.J. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Reson. Imaging 2009, 29(4):793-798.
18. Dröge W., Schipper H.M. Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell 2007, 6(3):361-370.
19. Ebaldi M., Srinivasan S.K., Baxi M.D. Oxidative stress and oxidant therapy in Parkinson's disease. Prog. Neurobiol. 1996, 48:1-19.
20. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., Archer T. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Relat. Disord. 2001, 7(2):97-105.
21. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., Archer T. Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Dev. Brain Res. 2000, 119:65-74.
22. Fredriksson A., Schröder N., Eriksson P., Izquierdo I., Archer T. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol. Appl. Pharmacol. 1999, 159:25-30.
23. Gerlach M., Double K.L., Youdim M.B., Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J. Neural. Transm. 2006, 70:133-142.
24. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vivo study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999, 122(4):667-673.
25. Haag M.D., Hofman A., Koudstaal P.J., Stricker B.H., Breteler M.M. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2009, 80(1):13-17.
26. Hayashi T., Hamakawa K., Nagotani S., Jin G., Li F., Deguchi K., Sehara Y., Zhang H., Nagano I., Shoji M., Abe K. HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res. 2005, 1037(1-2):52-58.
27. House, M.J., St. Pierre, T.G., Foster, J.K., Martins, R.N., Clarnette, R., 2006. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. A. J. N. R. 27, 430-439.
28. Ke Y., Qian Z.M. Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 2007, 83(3):149-173.
29. Kienzl E., Puchinger L., Jellinger K., Linert W., Stachellberger H., Jameson R.F. The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 1995, 134:69-78.
30. Koladiya R.U., Jaggi A.S., Singh N., Sharma B.K. Ameliorative role of atorvastatin and pitavastatin in L-Methionine induced vascular dementia in rats. BMC Pharmacol. 2008, 8:14.
31. Kosta P., Argyropoulou M.I., Markoula S., Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J. Neurol. 2006, 253(1):26-32.
32. Kumagai R., Oki C., Muramatsu Y., Kurosaki R., Kato H., Araki T. Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils. J. Neural. Transm. 2004, 111(9):1103-1120.
33. Kurinami H., Sato N., Shinohara M., Takeuchi D., Takeda S., Shimamura M., Ogihara T., Morishita R. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int. J. Mol. Med. 2008, 21(5):531-537.
34. Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002, 942(1-2):23-30.
35. Li L., Cao D., Kim H., Lester R., Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol. 2006, 60(6):729-739.
36. Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 1998, 158:47-52.
37. Lu D., Qu C., Goussev A., Jiang H., Lu C., Schallert T., Mahmood A., Chen J., Li Y., Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J. Neurotrauma 2007, 24(7):1132-1146.
38. Lynch T., Cherny R., Bush A.I. Oxidative processes in Alzheimer's disease: the role of Abeta-metal interactions. Exp. Gerontol. 2000, 35:445-451.
39. McGaugh J.L. Dissociating learning and performance: drug and hormone enhancement of memory storage. Brain Res. Bull. 1989, 23(4-5):339-345.
40. McGuinness B., Craig D., Bullock R., Passmore P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. 2009, 15(2):CD003160.
41. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 2001, 87:28B-32B.
42. Middleton L.E., Yaffe K. Promising strategies for the prevention of dementia. Arch. Neurol. 2009, 66(10):1210-1215.
43. Moos T. Brain iron homeostasis. Dan. Med. Bull. 2002, 49(4):279-301.
44. Ong W.Y., Farooqui A.A. Iron, neuroinflammation, and Alzheimer's disease. J. Alzheimer's Dis. 2005, 8(2):183-200.
45. Orr J.D. Statins in the spectrum of neurologic disease. Curr. Atheroscler. Rep. 2008, 10(1):11-18.
46. Otto A., Fontaine J., Tschirhart E., Fontaine D., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br. J. Pharmacol. 2006, 148(4):544-552.
47. Pietá Dias C., de Lima M.N.M., Presti-Torres J., Dornelles A., Garcia V.A., Scalco F.S., Guimarães M.R., Constantino L., Budni P., Dal-Pizzol F., Schröder N. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007, 146(4):1719-1725.
48. Pratico D., Clark C.M., Liun F., Rokach J., Lee V.Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 2002, 59(6):972-976.
49. Quintana C., Bellefqih S., Laval J.Y., Guerquin-Kern J.L., Wu T.D., Avila J., Ferrer I., Arranz R., Patino C. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 2006, 153(1):42-54.
50. Rampon C., Tang Y.P., Goodhouse J., Shimizu E., Kyin M., Tsien J.Z. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat. Neurosci. 2000, 3:238-244.
51. Schröder N., O'Dell S.J., Marshall J.F. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003, 49:89-96.
52. Schröder N., Fredriksson A., Vianna M.R.M., Roesler R., Izquierdo I., Archer T. Memory deficits in adult rats following postnatal iron administration. Behav. Brain Res. 2001, 124:77-85.
53. Schupp N., Schmid U., Heidland A., Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008, 199(2):278-287.
54. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 1997, 94:9866-9986.
55. Sparks L. Statins and cognitive function. J. Neurol. Neurosurg. Psychiatry 2009, 80(1):1-2.
56. Stefani M., Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr. Alzheimer Res. 2009, 6(1):15-29.
57. Thomas M., Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr. Opin. Neurol. 2004, 17(4):437-442.
58. Wahner A.D., Bronstein J.M., Bordelon Y.M., Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008, 70(16 Pt 2):1418-1422.
59. Wallis L.I., Paley M.N., Graham J.M., Grünewald R.A., Wignall E.L., Joy H.M., Griffiths P.D. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J. Magn. Reson. Imaging 2008, 28(5):1061-1067.
60. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.
61. Wu H., Lu D., Jiang H., Xiong Y., Qu C., Li B., Mahmood A., Zhou D., Chopp M. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J. Neurotrauma 2008, 25(2):130-139.
62. van der Most P.J., Dolga A.M., Nijholt I.M., Luiten P.G., Eisel U.L. Statins: mechanisms of neuroprotection. Prog. Neurobiol. 2009, 88(1):64-75.
63. Xu X., Wang Q., Zhang M. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 2008, 40(1):35-42.
64. Youdim M.B. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox. Res. 2008, 14(1):45-56.
65. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5(11):863-873.
66. Zipp F., Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 2006, 29(9):518-527.